Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity is well positioned for a longer-term earnings and multiple re-rating because its portfolio is increasingly high-margin and recurring, with about 80% recurring revenue, ~50% of revenue from life sciences, and a diagnostics franchise that remains durable even as China headwinds fade. Its life sciences business is levered to recovering pharma/biotech preclinical spending and emerging AI-driven screening demand, while Signals adds sticky lab software exposure across 47 of the top 50 global pharma and biotech companies and could benefit from new products and AI monetization. Diagnostics also supports the thesis, with pro forma 2Q growth of 11% and Reproductive Health near 90%+ market share, while FY26 guidance has already risen from 2-3% organic growth to 4-5%, suggesting improving execution and visibility.

Revvity is viewed negatively because its growth engines are slowing just as macro and funding conditions remain shaky, with biopharma and academic demand vulnerable to cyclical spending cuts, currency swings, and country risk across North America, Europe, and Asia. Its key businesses face mixed fundamentals: Euroimmun’s growth has decelerated, BioLegend’s reagents business is barely growing, and the Diagnostics franchise is still exposed to China-related policy pressure and a planned divestiture expected by the end of 2027, while reproductive health benefits from the GEL contract but faces tougher comps in Q4 2026 and a structural birth-rate headwind. Meanwhile, Signals software may be protected by switching costs, but a crowded AI market has lengthened customer evaluation cycles, and recent trends do not yet support the step-up implied by the company’s long-range growth expectations.